One of the latest advancements in the U.S. injectable fillers market is lidocaine-containing versions of popular hyaluronic acid fillers, reports the July 2010 issue of Cosmetic Surgery Times. Lidocaine is a local anesthetic that is injected directly into the body area and decreases pain by temporarily numbing that area, according to WebMD.
Three injectables won FDA approval in February 2010 for lidocaine versions in the U.S.:
The products performed similarly to their lidocaine-free predecessors in terms of safety and efficacy, according to Dr. Michael H. Gold, a clinical assistant professor of dermatology at Vanderbilt University School of Medicine and School of Nursing. Furthermore, “The incorporation of lidocaine has surely provided a higher comfort level for patients [in the clinical trials],” he says.
Dr. Gold adds that in his clinical experience when patients undergo an injection that includes even a small percentage of lidocaine, “Most patients say they barely feel the second stick. To me that is the home run of lidocaine in these fillers.”
In clinical studies by Medicis to support FDA approval, the addition of lidocaine to Restylane and Perlane substantially reduced pain experienced by patients, while demonstrating adverse event safety profiles similar to those of Restylane and Perlane, according to the Medicis release.
A method for doctors mixing lidocaine with Radiesse was cleared in July 2009. “Originally, I was against doctors mixing a lot of fillers because I was afraid of potential changes in the products themselves,” says Dr. Gold. But once the FDA clears these products, especially those premixed by manufacturers, “I’m pretty comfortable with it.”
“Fillers with lidocaine among latest injectable advancements” is available online at Modern Medicine. Learn more about Restylane, Perlane, and Radiesse in Seattle.
Tags: fillers, Perlane, Radiesse, Restylane
This entry was posted on Tuesday, June 22nd, 2010 at 11:29 am and is filed under In The News, wrinkle fillers. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
